Pfizer-BioNTech announce early positive update from German phase 1/2 COVID-19 vaccine study
|Biopharmaceutical New Technologies (BioNTech) and Pfizer announced on Monday that they have received early positive results from the German phase one and two trials of their co-developed coronavirus vaccine (BNT162B1).
Key takeaways
"New preliminary data from German study support and expand upon recently disclosed early results from corresponding US trial with BNT162B1."
"Overall, data suggested that BNT162B1 could potentially be administered safely, with a manageable tolerability profile."
Market reaction
This headline seems to be providing a boost to market sentiment. At the moment, the S&P 500 futures are posting small daily gains and Germany's DAX 30 Index is up 0.55%.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.